期刊文献+

尿毒症血清促进脐静脉内皮细胞活性氧、白介素-6的产生及左旋肉毒碱的干预作用 被引量:3

Effect of L-carnitine on the expression of IL-6 and reactive oxygen species in human umbilical vein endothelial cells cultured in medium containing uremic serum
暂未订购
导出
摘要 目的观察体外尿毒症血清环境诱导的脐静脉内皮细胞(HUVEC)活性氧(ROS)及白介素-6(IL-6)的产生及左旋肉毒碱(L-CN)对它们的影响。方法以2、7-二氢二氯荧光素染色(DCFH)和荧光分光光度计法检测ROS强度,RT-PCR和ELISA方法检测IL-6表达,观察尿毒症血清对HUVEC的影响和不同浓度L-CN(25μM,250μM,1000μM,2500μM)的干预作用。结果尿毒症血清环境能使细胞内ROS产生及IL-6表达明显增加;而L-CN可明显抑制尿毒症血清环境中细胞内ROS产生及IL-6表达,且有浓度依赖效应。结论尿毒症血清促使血管内皮微炎症状态的建立,L-CN可抑制其组织活性氧及白介素-6的产生,减轻尿毒症患者慢性炎症反应,对血管粥样硬化病变可能有延缓作用。 Objective To observe the effect of uremic serum on the production of reactive oxygen species (ROS) and interleukin-6 (IL-6) in human umbilical vein endothelial cells (HUVEC), and its intervention by L-carnitine (L-CN). Methods Uremic sera mixed with various concentrations of L-CN (0, 25, 250, 1000 and 2500μM) were added to the culture medium. Semi-quantitative RT-PCR and ELISA were applied to evaluate the expression of IL-6. Cells labeled with oxidation-susceptible fluorescent probe 2,7-dichorofluoresin diacetate (DCFH) and measured by spectrofluorophotometer were used for ROS assay. Results IL-6 and ROS were increased in HUVEC in the presence of uremic serum. With the addition of L-CN (250μM-2500μM) in culture medium, the production of ROS and IL- 6 in HUVEC was inhibited, and the inhibition was L-CN concentration dependent. Conclusion Uremic serum induces the micro-inflammation processes of blood vessel endothelia. L-CN inhibits the production of ROS and IL-6 in HUVEC and thus the microinflammation and atherosclerosis processes in uremic patients.
出处 《中国血液净化》 2007年第10期534-537,共4页 Chinese Journal of Blood Purification
关键词 人脐静脉内皮细胞 活性氧 白介素-6 终末期肾病 左旋肉毒碱 Human umbilical vein endothelial cell IL-6 Reactive oxygen species L-carnitine Uremia
  • 相关文献

参考文献14

  • 1中华医学会肾脏病分会透析移植登记工作组,钱家麒,张伟明,徐筱琪.1999年度全国透析移植登记报告[J].中华肾脏病杂志,2001,17(2):77-78. 被引量:444
  • 2梁敏,侯凡凡,刘志强,王力,田建伟.终末期肾病患者脂质过氧化水平的变化[J].肾脏病与透析肾移植杂志,2003,12(4):324-326. 被引量:8
  • 3Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end - stage renal disease[J]. Int Heart J, 2005,46(2):255-264.
  • 4Dursun E, Dursun B, Suleymanlar G, et al. Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus[J]. Acta Diabetol, 2005,42:123-128.
  • 5Tzoulaki I, Murray GO, Lee AJ, et al. C-reactive protein, interleukin 6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population. Edinburgh Artery Study[J]. Circulation, 2005, 112(8):976-983.
  • 6Vincenzo P, Umberto M, Daniele T, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients[J]. Nephrol Dial Transplant, 2004,19:1154-1160.
  • 7Teng BQ, Murthy KS, Kuemmerle JF, et al. Expression of endothelial nitric oxide synthase in human and rabbit gastriontestinal smooth muscle cells[J]. Am J Phvsiol, 1998, 275:G342-351.
  • 8Popik W, Hesselgesser JE, Pitha PM. Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 recepors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway[J]. J Viol,1998, 72(8) 6406-6410.
  • 9George A. The microinflammatory state in uremia: causes and potential consequences[J]. J Am Soc Nephrol,2001,12:1549-1557.
  • 10申玉兰,彭立人,周亦伦.左旋肉碱对维持性血液透析患者微炎症、营养不良和贫血的影响[J].中国血液净化,2007,6(2):92-93. 被引量:11

二级参考文献21

  • 1Yla-Herttuala S.Is oxidized low-density lipoprotein present in vivo? Curr Opin Lipidol, 1998,9:337.
  • 2Epperlein MM, Nourooz-Zadeh J, Jayasena SD, et al. Nature and biological significance of free radicals generated during bicarbonate hemodialysis. J Am Soc Nephrol, 1998, 9:457.
  • 3Witztum TL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 1991, 88:1785.
  • 4Mei Zhon, Yuan Chen, Shang Xi Liu, et al. Oxidative and malondialdehyde modification of low density lipoprotein: a comparative study of binding and degradation by macrophage and endothelial cells. Brit J Biomed Sci, 1998, 55:192.
  • 5Bonomini M, Sirolli V, Settefrati N, et al. Increased erythrocyte phosphatidyl-serine exposure in chronic renal failure. J Am Soc Nephrol,1999, 10:1982.
  • 6Martin-Mateo MC, Canto-Jafiez E, Barrero-Martinez MJ. Oxidative stress and enzyme activity in ambulatory renal patient undergoing continuous peritoneal dialysis. Renal Failure, 1998, 20:117.
  • 7Roob JM, Rabold T, Hayn M, et al. Ex vivo low-density lipoprotein oxidizabiliby and in vivo lipid peroxidation in patients on CAPD. Kidney Int,2001,78: S128.
  • 8US renal data system USRDS 1991 : Annual Data Report. Beshesda. The national of health, national institute of diabetes and digestive and kidney diseases, 1991.
  • 9Witztum JL. Role of oxidised low density lipoprotein in atherogenesis. Br Heart J, 1993, 69(Suppl):S12.
  • 10Pryor WA. On the detection of lipid hydroperocides in biological samples.Free Radic Biol Med,1989,7:177

共引文献460

同被引文献30

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部